Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses the logistical implications of implementing tyrosine kinase inhibitor (TKI) treatments across different European countries. She highlights the differences in screening and treatment policies between countries, and explains how to improve these discrepancies in the future.
The reality of implementing TKI therapies for NSCLC in Europe
